Journalism of Courage
Advertisement
Premium

After the bang

Companies Bill brings a modern frame for business. Changes in Competition Act raise new questions

It could be third time lucky for the Companies Bill,after cabinet clearances in 2008 and 2011. The principal opposition party,the BJP,has declared its support for the bill,unlike the last time when it had raised objections over some of the clauses being changed from the draft cleared by the standing committee. The partys support means the bill will not have to pass the committee stage again and could become an act,13 years after it was first proposed. In its provisions and fine print,the bill will be of deep significance to the corporate sector. In the absence of an updated law,a significant part of the working of Indian companies,public and private,is based on conventions and approvals from other mechanisms like the Listing Agreement. The ramifications for the sector of such ad hoc guidelines,and the absence of rule-based operations,was apparent in several cases,of which Satyam was only the first one.

There is no clarity,for instance,in the current Companies Act 1956 on the extent to which the board members of a company can be hauled up for corporate malfeasance. The provisions for private placement,too,are few. Yet 1,500 Indian companies raised a massive Rs 2.39 lakh crore through this route in just eight months this year,as per Sebi data. Money raised from the equity markets was only Rs 1,217 crore in the same period. Similarly,allowing companies with multiple lines of business to separate the posts of the chairman and managing directors will provide them with more flexibility to take decisions than is possible under the current law.

The related cabinet approval for modifying the Competition Act is,however,more controversial. The government aims to give a far wider role to the Competition Commission of India by the amendments,including a say in mergers and acquisitions in the financial sector. It will be interesting to see what value CCI can add here,considering an RBI ex ante approval is necessary for any acquisition of shares by any entity plus the exercise of fit and proper criteria. In the case of the pharma sector,the changes mean all mergers and acquisitions come under the CCI ambit. There are grey areas. Would all foreign investments above 51 per cent need to be cleared by the CCI before FIPB approvals,for instance? Since these changes will not come before the standing committee again,the government needs to search for regulations that do not impact the necessary rise and fall of companies.

Curated For You

 

Tags:
  • editorial Indian Express
Edition
Install the Express App for
a better experience
Featured
Trending Topics
News
Multimedia
Follow Us
Sharper, light touchWhy Priyanka Gandhi has got people talking
X